San antonio Genetics Corporation. SGEN, +.78% stated Monday that it’s discontinuing the Phase 3 medical trial of their acute myeloid leukemia treatment, SGN-CD33A, after data indicated a greater rate of deaths, including fatal infections. The organization stated it’ll suspend patient enrollment and treatment, and can carefully evaluate the data and talk to the Fda to find out future plans. “This can be a disappointing and unpredicted result for that CASCADE trial. Patient safety factors are our greatest priority, and we’ll carefully evaluate the data and evaluate next steps,” stated Leader Clay Siegall. The stock, that is still inactive in premarket trade, has rallied 22% year up to now through Friday, as the iShares Nasdaq Biotechnology ETF IBB, -.36% has rose 10% and also the S&P 500 SPX, +.03% has acquired 8.7%.